Hypha Labs (FUNI) 10-K 9 Jan 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2016	Jan. 06, 2017	Mar. 31, 2016
Document And Entity Information
Entity Registrant Name	DigiPath,Inc.
Entity Central Index Key	1,502,966
Document Type	10-K
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 5,312,981
Entity Common Stock, Shares Outstanding		24,991,041
Trading Symbol	DIGP
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Current assets:
Cash	$ 135,390	$ 481,095
Accounts receivable	98,441	6,146
Inventory		192,561
Prepaid expenses	24,246	60,447
Deposits	39,850	44,949
Total current assets	297,927	785,198
Fixed assets, net	1,139,748	1,373,691
Available-for-sale securities	9,200	14,000
Total Assets	1,446,875	2,172,889
Current liabilities:
Accounts payable	157,666	62,383
Accrued expenses	54,247	21,671
Deferred revenues		73,121
Total current liabilities	211,913	157,175
Total Liabilities	211,913	157,175
Stockholders' Equity:
Series A convertible preferred stock, $0.001 par value, 10,000,000 shares authorized; 3,520,442 and 4,351,442 shares issued and outstanding at September 30, 2016 and 2015, respectively	3,520	4,351
Common stock, $0.001 par value, 90,000,000 shares authorized; 22,491,041 and 13,762,705 shares issued and outstanding at September 30, 2016 and 2015, respectively	22,491	13,763
Additional paid-in capital	11,681,282	10,224,551
Accumulated other comprehensive loss	(40,800)	(36,000)
Accumulated (deficit)	(10,431,531)	(7,847,418)
Total Digipath, Inc. Stockholders' Equity	1,234,962	2,359,247
Noncontrolling interest		(343,533)
Total Stockholders' Equity	1,234,962	2,015,714
Total Liabilities and Stockholders' Equity	$ 1,446,875	$ 2,172,889

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Sep. 30, 2015
Statement of Financial Position [Abstract]
Series A Convertible Preferred stock, par value	$ 0.001	$ 0.001
Series A Convertible Preferred stock, shares authorized	10,000,000	10,000,000
Series A Convertible Preferred stock, shares issued	3,520,442	4,351,442
Series A Convertible Preferred stock, shares outstanding	3,520,442	4,351,442
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	22,491,041	13,762,705
Common stock, shares outstanding	22,491,041	13,762,705

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenues	$ 818,583	$ 16,084
Cost of sales	380,036	85,551
Gross profit (loss)	438,547	(69,467)
Operating expenses:
General and administrative	1,016,243	1,564,003
Professional fees	1,785,819	1,730,171
Bad debt expense	274,375
Depreciation and amortization	244,580	77,813
Total operating expenses	3,321,017	3,371,987
Operating loss	(2,882,470)	(3,441,454)
Other income (expense):
Other income	154,000	36,000
Interest income	10,000
Loss on disposal of fixed assets		(8,303)
Loss on impairment of intangible asset		(300,000)
Gain on early extinguishment of debt	12,133
Equity in losses of unconsolidated entity	(992,682)
Total other income (expense)	(816,549)	(272,303)
Net loss from continuing operations	(3,699,019)	(3,713,757)
Less: Net loss attributable to the noncontrolling interest
Net loss attributable to Digipath, Inc. from continuing operations	(3,699,019)	(3,713,757)
Loss from operations of discontinued business component		(618,572)
Net loss	$ (3,699,019)	$ (4,332,329)
Weighted average number of common shares outstanding - basic and fully diluted	18,438,048	9,906,468
Net (loss) per share - basic and fully diluted	$ (0.20)	$ (0.37)
Net loss attributable to Digipath, Inc.	$ (3,699,019)	$ (4,332,329)
Available-for-sale investments:
Change in net unrealized loss (net of tax effect)	(4,800)	(36,000)
Comprehensive loss	$ (3,703,819)	$ (4,368,329)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Non-Controlling Interest [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated (Deficit) [Member]	Total
Balance at Sep. 30, 2014	$ 5,850	$ 5,876	$ 9,333,795	$ (343,533)		$ (3,515,089)	$ 5,486,899
Balance, shares at Sep. 30, 2014	5,850,000	5,875,640
Common stock issued for services		$ 237	223,775				224,012
Common stock issued for services, shares		237,545
Common stock options issued for services			663,626				663,626
Conversion of preferred stock to common stock	$ (1,499)	$ 7,722	(6,223)
Conversion of preferred stock to common stock, shares	(1,498,558)	7,721,639
Options exercised for cash		$ 3	9,503				$ 9,506
Options exercised for cash, shares		2,881					(2,881)
Cancellation of common stock		$ (75)	75
Cancellation of common stock, shares		(75,000)
Unrealized loss on available-for-sale securities					(36,000)		(36,000)
Net loss						(4,332,329)	(4,332,329)
Balance at Sep. 30, 2015	$ 4,351	$ 13,763	10,224,551	(343,533)	(36,000)	(7,847,418)	2,015,714
Balance, shares at Sep. 30, 2015	4,351,442	13,762,705
Deconsolidation of subsidiary, Digipath Corp			(408,941)	343,533		1,114,906	1,049,498
Units of common stock and warrants sold for cash		$ 3,033	456,967				460,000
Units of common stock and warrants sold for cash, shares		3,033,336
Common stock issued for services		$ 1,840	293,318				295,158
Common stock issued for services, shares		1,840,000
Common stock options issued for services			1,118,411				1,118,411
Cancellation of preferred stock	$ (60)		60
Cancellation of preferred stock, shares	(60,000)
Conversion of preferred stock to common stock	$ (771)	$ 3,855	(3,084)
Conversion of preferred stock to common stock, shares	(771,000)	3,855,000
Options exercised for cash, shares
Unrealized loss on available-for-sale securities					(4,800)		$ (4,800)
Net loss						(3,699,019)	(3,699,019)
Balance at Sep. 30, 2016	$ 3,520	$ 22,491	$ 11,681,282		$ (40,800)	$ (10,431,531)	$ 1,234,962
Balance, shares at Sep. 30, 2016	3,520,442	22,491,041

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities
Net loss	$ (3,699,019)	$ (4,332,329)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	274,375
Depreciation and amortization expense	244,580	83,725
Stock issued for services	295,158	224,012
Options and warrants granted for services	1,118,411	663,626
Loss on disposal of fixed assets		8,303
Loss on impairment of development costs		28,336
Loss on impairment of intangible asset		300,000
Gain on early extinguishment of debt	(12,133)
Equity in losses of unconsolidated entity	992,682
Decrease (increase) in assets:
Accounts receivable	(103,545)	74,385
Inventory		92,694
Prepaid expenses	(979)	21,323
Deposits	(675)	(8,914)
Increase (decrease) in liabilities:
Accounts payable	128,666	(63,471)
Accrued expenses	32,576	(4,239)
Deferred revenues	(4,167)	33,988
Net cash used in operating activities	(734,070)	(2,836,047)
Cash flows from investing activities
Cash disposed in divestiture of unconsolidated entity	(57,876)
Purchase of fixed assets	(13,759)	(1,444,984)
Purchase of intangible assets		(300,000)
Purchase of available-for-sale securities		(50,000)
Net cash used in investing activities	(71,635)	(1,794,984)
Cash flows from financing activities
Proceeds from exercised options		9,506
Proceeds from sale of common stock	460,000
Net cash provided by financing activities	460,000	9,506
Net increase (decrease) in cash	(345,705)	(4,621,525)
Cash - beginning	481,095	5,102,620
Cash - ending	135,390	481,095
Supplemental disclosures:
Interest paid
Income taxes paid
Non-cash investing and financing activities:
Value of preferred stock converted to common stock	$ 831,000	$ 1,498,558

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our business units as of September 30, 2016 are described below. ● Digipath Labs, Inc ● The National Marijuana News Corp Stock Split All share and per share amounts herein have been given retroactive effect to the 1-for-10 reverse stock split of the Company’s common stock effected May 27, 2015 (See Note 12). Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2016: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) (2) (3) The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Equity Method Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Consolidated Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Consolidated Statements of Operations. The Company’s carrying value in an equity method Investee company is reflected in the caption “Investment in Digipath Corp.” in the Company’s Consolidated Balance Sheets. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized. Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of three months or less. The Company had no cash equivalents as of September 30, 2016 and 2015. Cash in Excess of FDIC Insured Limits The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 under current regulations. The Company had approximately $-0- and $231,095 in excess of FDIC insured limits at September 30, 2016 and 2015, respectively. The Company has not experienced any losses in such accounts. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $-0- and $36,715 as of September 30, 2016 and 2015, respectively. Inventory Inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out method. Inventory consists of digital slide scanners and slide scanner parts. Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 2-3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements 6 years Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which have extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. The Company recognized impairment losses on the disposal of fixed assets of $-0- and $8,303 during the years ended September 30, 2016 and 2015, respectively. Our intellectual property is comprised of indefinite-lived brand name acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. The Company recognized an impairment loss on the carrying value of its investment in TissueBLOX TM Marketable Securities The Company classifies its debt and marketable equity securities into held-to-maturity, trading, or available-for-sale categories. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders’ equity. Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. With respect to our cannabis lab testing revenues, we sell our services on a determinable fixed fee per test, or panel of tests basis, and offer a discounted price for customers that agree to enter into exclusive, long term contracts. We typically require payment within thirty days of the delivery of results. Revenues are recognized upon the substantial completion of the tests when collectability is reasonably assured, which is usually upon delivery of results to the customer. Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $121,610 and $139,119 for the years ended September 30, 2016 and 2015, respectively. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2016 and 2015, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. Recent Accounting Pronouncements In August, 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In June, 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718) . In March, 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March, 2016, the FASB issued ASU No. 2016-07, Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. In March, 2016, the FASB issued ASU No. 2016-04, Liabilities—Extinguishments of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Products In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of ($10,431,531), and as of September 30, 2016, the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Discontinued Business Component

Discontinued Business Component	12 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Discontinued Business Component	Note 3 – Discontinued Business Component The digital pathology business operating under the subsidiary Digipath Corp. has been accounted for as a discontinued business component. The results of operations of this business have been removed from the results of continuing operations for all periods presented within our statements of operations. In October of 2015, Digipath, Inc., divested approximately two-thirds of its ownership of Digipath Corp. to warrant holders of Digipath Corp. through the sale of common stock and the exercise of warrants, including warrants held by Steven D. Barbee, our former Director. As a result, our interest in Digipath Corp. is accounted for pursuant to the equity method of accounting due to our lack of control and reduced ownership percentage of approximately 33.3%. Digipath Corp. continues to operate. However, the change in accounting method for Digipath, Inc. necessitates the deconsolidation of Digipath Corp. be retrospectively presented as a discontinued business component. The operating results of the Digital Pathology business for the year ended September 30, 2015 (prior to our divestment of control of this business), which have been extracted and presented as “Loss from operations of discontinued business component” within the statements of operations, are summarized below: For the Year Ended September 30, 2015 Revenues $ 395,718 Cost of sales 360,652 Gross profit 35,066 Expenses: General and administrative 433,569 Research and development 220,432 Total operating expenses 654,001 Net operating loss, net of tax (618,935 ) Other income 363 Net loss, net of tax $ (618,572 )

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions Appointment of Joseph J. Bianco as Chief Executive Officer On June 21, 2016, the Board appointed Joseph J. Bianco, one of our directors, to serve as the Company’s Chief Executive Officer. As described further below, Todd Denkin, the Company’s Chief Executive Officer prior to such appointment, now serves as the Company’s President and Chief Operating Officer, and as the President of Digipath’s wholly-owned subsidiaries, Digipath Labs, Inc. and TNM News Corp. In connection with his appointment as Chief Executive Officer, Mr. Bianco entered into an Employment Agreement with the Company dated June 21, 2016 for a three year term, and providing for an initial base salary of $96,000 per annum and a car allowance of $1,250 per month. Pursuant to this Employment Agreement, Mr. Bianco was awarded a stock option to purchase 4,750,000 shares of the Company’s common stock at an exercise price of $0.20 per share. The option vests immediately as to one-half of the shares, one year from the grant date as to one-quarter of the shares, and two years following the grant date as to the remaining one-quarter of the shares. The Employment Agreement also terminated the letter agreement between Mr. Bianco’s affiliate and the Company pursuant to which Mr. Bianco had provided consulting services to the Company. Todd Denkin Amended and Restated Employment Agreement In connection with Mr. Bianco’s appointment as the Company’s Chief Executive Officer, on June 21, 2016, the Company entered into an Amended and Restated Employment Agreement with Todd Denkin, pursuant to which Mr. Denkin continues to serve as the Company’s President, and in addition as its Chief Operating Officer, and as the President of Digipath’s wholly-owned subsidiaries, Digipath Labs, Inc. and TNM News Corp. In addition, the term of Mr. Denkin’s employment has been extended for a period of three years from June 21, 2016, and he will continue to be paid a base salary of $192,000 per annum, and receives a car allowance of $750 per month. Pursuant to the Amended and Restated Employment Agreement, Mr. Denkin was awarded a stock option to purchase 2,500,000 shares of the Company’s common stock at an exercise price of $0.20 per share. The option vests immediately as to one-half of the shares, one year from the grant date as to one-quarter of the shares, and two years following the grant date as to the remaining one-quarter of the shares. Stock Issued to CFO for Services On September 30, 2016, the Company issued 300,000 shares of common stock to its CFO as a bonus for services rendered. The aggregate fair value of the common stock was $59,970 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. Options Issued to CFO for Services On June 19, 2015, the Company granted an option to purchase 100,000 shares of common stock as compensation for services to our Chief Financial Officer. The option vests ratably in quarterly increments over one (1) year beginning September 19, 2015. The options are exercisable until June 19, 2025 at an exercise price of $0.33 per share. The estimated fair value using the Black-Scholes Pricing Model, based on a volatility rate of 237% and a call option value of $0.3274, was $32,744. The option is being expensed over the vesting period. Divestiture of Wholly-Owned Subsidiary, Digipath Corp. On October 1, 2015, Digipath, Inc., entered into an Omnibus Agreement and Amendment (the “Agreement”) with Digipath Corp., and our former Director, Steven D. Barbee. Pursuant to the Agreement, among other things: ● The exercise price of the warrant held by Mr. Barbee to purchase 3,000,000 shares of common stock of Digipath Corp. (the “Barbee Warrant”) was reduced from $0.10 per share to $0.0333333 per share, and Mr. Barbee subsequently exercised the warrant. ● Mr. Barbee resigned as a director of the Company. ● The Consulting, Confidentiality and Proprietary Rights Agreement, dated as of May 30, 2014, between the Company and Mr. Barbee, as amended, was terminated. ● Indebtedness of approximately $18,201 owed by the Company to Digipath Corp. was cancelled. ● Digipath Corp. was provided with the right to require the Company to change its name so as not to include the name “Digipath” in the event of the sale of all or substantially all of the assets or capital stock of Digipath Corp., or a merger of Digipath Corp. following which the Company ceases to be a shareholder of Digipath Corp., in each case, that occurs within 12 months following the date of the Agreement. ● The Company, as a shareholder of Digipath Corp, was provided with (i) rights of first-refusal and co-sale rights with respect to sales of common stock of Digipath Corp by Barbee, and (ii) pre-emptive rights with respect to issuances of common stock by Digipath Corp. Concurrently with the execution of the Agreement, Digipath Corp. agreed to issue 3,000,000 shares of its common stock to a third party for an aggregate purchase price of $100,000, and an affiliate of such party agreed to surrender 60,000 shares of Series A Preferred of the Company for cancellation, and terminate a previously held warrant to purchase 3,000,000 shares of common stock of Digipath Corp. As a result of such issuance of shares of Digipath Corp common stock, and after giving effect to the exercise of the Barbee Warrant, the Company continued to hold approximately 33.34% of the outstanding shares of common stock of Digipath Corp. Following the execution of the Agreement, Mr. Barbee continued to serve as the President and sole director of Digipath Corp.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 5 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2016 and 2015, respectively: Fair Value Measurements at September 30, 2016 Level 1 Level 2 Level 3 Assets Cash $ 135,390 $ - $ - Available-for-sale securities 9,200 - - Total assets 144,590 - - Liabilities None - - - Total liabilities - - - $ 144,590 $ - $ - Fair Value Measurements at September 30, 2015 Level 1 Level 2 Level 3 Assets Cash $ 481,095 $ - $ - Intellectual properties 14,000 - - Total assets 495,095 - - Liabilities None - - - Total liabilities - - - $ 495,095 $ - $ - The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended September 30, 2016 or 2015. We recognized total impairment losses of $-0- and $300,000 on our intellectual properties during the years ended September 30, 2016 and 2015, respectively.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Accounts Receivable	Note 6 – Accounts Receivable Accounts receivable was $98,441 and $6,146 at September 30, 2016 and 2015, respectively, net of allowance for uncollectible accounts of $-0- and $36,715 at September 30, 2016 and 2015, respectively.

Inventory

Inventory	12 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory	Note 7 – Inventory Inventory was $-0- and $192,561 at September 30, 2016 and 2015, respectively. There is no allowance for inventory obsolescence. A total of $-0- and $73,179 was written off due to obsolescence and included in the loss from operations of discontinued business component within the consolidated statements of operations during the years ended September 30, 2016 and 2015, respectively.

Fixed Assets

Fixed Assets	12 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 8 – Fixed Assets Fixed assets consist of the following at September 30, 2016 and 2015: For the Years Ended September 30, 2016 2015 Software $ 121,617 $ 131,636 Office equipment 36,080 35,467 Furniture and fixtures 2,357 14,607 Lab equipment 811,623 835,006 Leasehold improvements 487,066 487,066 1,458,743 1,503,782 Less: accumulated depreciation (318,995 ) (130,091 ) Total $ 1,139,748 $ 1,373,691 On October 1, 2016, we disposed of fixed assets with a net book value of $3,122 pursuant to the deconsolidation of Digipath Corp. The fixed assets consisted of furniture and fixtures with a historical cost basis of $48,779 and software with a historical cost basis of $10,019, and accumulated depreciation of $48,779 and $6,897, respectively. No gain or loss was recognized on the disposals. During the year ended September 30, 2015, we realized a loss on the disposal of leasehold improvements in the amount of $8,303 when we terminated a lease whereby we had capitalized improvements with a historical cost basis of $13,586 and a net carrying value of $8,303 upon disposal. Depreciation and amortization expense totaled $244,580 and $77,813 for the years ended September 30, 2016 and 2015, respectively.

Available-for-Sale Securities

Available-for-Sale Securities	12 Months Ended
	Sep. 30, 2016
Schedule of Investments [Abstract]
Available-for-Sale Securities	Note 9 – Available-for-Sale Securities Available-for-sale securities consist of the following at September 30, 2016: Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Income Income Value Common stock $ 50,000 - $ (40,800 ) $ 9,200 Total available-for-sale securities $ 50,000 - $ (40,800 ) $ 9,200 Common stock consists of 400,000 shares of common stock of Blue Line Protection Group, Inc., a Nevada corporation, acquired from the issuer in March of 2015 for $50,000.

Intangible Assets

Intangible Assets	12 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 10 – Intangible Assets For the year ended September 30, 2015, the Company determined that the carrying value of its intangible assets were impaired. As a result, we recognized a loss on impairment of $300,000 during the year ended September 30, 2015. The Company recognized an impairment loss on the carrying value of its investment in TissueBLOX TM

Deferred Revenues

Deferred Revenues	12 Months Ended
	Sep. 30, 2016
Deferred Revenue Disclosure [Abstract]
Deferred Revenues	Note 11 – Deferred Revenues Deferred revenues consist of the following at September 30, 2016 and 2015, respectively. For the Years Ended September 30, 2016 2015 Unearned advertising revenue $ - $ 4,167 Unearned software support - 68,954 Total $ - $ 73,121

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Stockholders' Equity	Note 12 – Stockholders’ Equity Reverse Stock Split On May 27, 2015, the Company effected a 1-for-10 reverse stock split (the “Reverse Stock Split”). No fractional shares were issued, and no cash or other consideration was paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. The Company was authorized to issue 900,000,000 shares of common stock prior to the Reverse Stock Split. As a result of the Reverse Stock Split, the Company’s authorized shares decreased ratably to 90,000,000 shares of common stock. The Reverse Stock Split did not have any effect on the stated par value of the common stock, or the Company’s authorized preferred stock. Unless otherwise stated, all share and per share information in this Annual Report on Form 10-K has been retroactively adjusted to reflect the Reverse Stock Split. Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, of which 6,000,000 have been designated as Series A Convertible Preferred Stock (“Series A Preferred”). As of September 30, 2016, there are 3,520,442 shares of Series A Preferred issued and outstanding. The Board of Directors is authorized to determine any number of series into which shares of preferred stock may be divided and to determine the rights, preferences, privileges and restrictions granted to any series of the preferred stock. Effective as of April 4, 2014, the designations, rights and preferences of the preferred shares changed to blank check preferred. The conversion price of the Series A Preferred is currently $0.20 per share. The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 3,520,442 shares of Series A Preferred outstanding at September 30, 2016 are convertible into 17,602,210 shares of the common stock of the Company. No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99% beneficial ownership limitation described above. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series A Preferred plus all accrued but unpaid dividends. ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99% beneficial ownership limitation described above. The Series A Preferred generally will vote together with the common stock and not as a separate class, except as provided below. ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Preferred Stock Conversions for the Year Ended September 30, 2016 For the year ended September 30, 2016, a total of 771,000 shares of Series A Preferred were converted into 3,855,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Preferred Stock Conversions for the Year Ended September 30, 2015 For the year ended September 30, 2015, a total of 1,498,558 shares of Series A Preferred were converted into 7,721,685 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Common stock consists of $0.001 par value, 90,000,000 shares authorized, of which 22,491,041 shares were issued and outstanding as of September 30, 2016. Common Stock Sales for the Year Ended September 30, 2016 On May 2, 2016, the Company sold 100,000 units, consisting of 100,000 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $15,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On April 29, 2016, the Company sold 166,667 units, consisting of 166,667 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $25,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On April 14, 2016, the Company sold 166,667 units, consisting of 166,667 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $25,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On April 12, 2016, the Company sold 83,334 units, consisting of 83,334 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $12,500. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On April 7, 2016, the Company sold 166,667 units, consisting of 166,667 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $25,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On March 15, 2016, the Company sold 1,666,667 units, consisting of 1,666,667 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $250,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On February 17, 2016, the Company sold 83,333 units, consisting of 83,333 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $12,500. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On January 19, 2016, the Company sold 333,334 units, consisting of 333,334 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On December 21, 2015, the Company sold 166,667 units, consisting of 166,667 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $25,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On November 23, 2015, the Company sold 100,000 units, consisting of 100,000 shares of its common stock and an equal number of warrants, exercisable at $0.40 per share over a thirty six month period, in exchange for total proceeds of $20,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. Additional Common Stock Issuances for the Year Ended September 30, 2016 On September 30, 2016, the Company issued 300,000 shares of common stock to its CFO as a bonus for services rendered. The aggregate fair value of the common stock was $59,970 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On September 30, 2016, a total of 120,000 shares of common stock were issued to three consultants for services previously rendered. The aggregate fair value of the common stock was $23,988 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On July 1, 2016, a total of 580,000 shares of common stock were issued to six consultants that were engaged to assist the Company with acquisition activities over for a three month period. The aggregate fair value of the common stock was $104,980 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the three month requisite service period. On February 1, 2016, a total of 300,000 shares of common stock were awarded to three consultants that were engaged to assist with acquisition activities over for a three month period. The aggregate fair value of the common stock was $45,720 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the three month requisite service period, resulting in $30,480 of stock based compensation during the period. On January 1, 2016, the Company issued 40,000 shares of restricted common stock for investor relations services provided. The total fair value of the common stock was $8,000 based on the closing price of the Company’s common stock on the date of grant and was expensed in full. On January 1, 2016, an affiliate of Mr. Bianco, a director of the Company, became entitled to receive 500,000 shares of common stock for consulting services to be performed during 2016, subject to a ratable “claw back” provision the event of an early termination of the consulting agreement. The total fair value of the common stock was $70,000 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the twelve month requisite service period, resulting in $52,500 of stock based compensation during the period. Common Stock Issuances for the Year Ended September 30, 2015 On August 10, 2015, the Company issued 25,000 shares of restricted common stock for professional services provided. The total fair value of the common stock was $5,887 based on the closing price of the Company’s common stock on the date of grant. During the quarter ended March 31, 2015, the Company issued 40,000 shares of common stock and cancelled 75,000 shares of common stock associated with transactions fully recorded in a previous period. During the same period, the Company issued 12,500 shares of common stock and recognized compensation expense associated with the issuance and vesting of these shares in the amount of $23,063. During the quarter ended December 31, 2014, the Company cancelled 1,219,589 non-plan options and issued 1,110,000 plan options and 500,000 warrants with exercise prices ranging from $0.30 to $0.85 per share, vesting immediately. The Company recorded the replacement of the stock options award as a modification of the terms of the cancelled awards, with the total compensation cost measured at the date of cancellation and replacement as being the sum of the portion of the grant-date fair value of the original award for which the requisite compensation expense had already been recognized at that date plus the incremental cost resulting from the cancellation and replacement. The Company recorded a net total of $845,540 stock option compensation expense related to these issuances and cancellations. During the quarter ended December 31, 2014, the Company issued 2,881 shares associated with the exercise of options with an exercise price of $3.30 per share and received $9,506 in cash. During the same period, the Company approved the issuance of 160,000 shares of the Company’s common stock and recognized $114,083 of compensation expense associated with the issuance and vesting of these shares, and additional compensation expense of $68,333 for the vesting of prior period awards.

Common Stock Options

Common Stock Options	12 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock Options	Note 13 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012 and previously amended on May 20, 2014. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 shares of common stock pursuant to the grant of options or other awards, including stock grants, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2012 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. Common Stock Option Issuances for the Year Ended September 30, 2016 On June 21, 2016, the Company granted options to purchase 4,750,000 shares of common stock as compensation for services to our CEO, Mr. Bianco. The options are exercisable over a ten year period at an exercise price of $0.20 per share, and 50% vest immediately, with 25% vesting each year thereafter. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 230% and a call option value of $0.1986, was $943,193. The options are being expensed over the vesting period. On June 21, 2016, the Company granted options to purchase 2,500,000 shares of common stock as compensation for services to our President and COO, Mr. Denkin. The options are exercisable over a ten year period at an exercise price of $0.20 per share, and 50% vest immediately, with 25% vesting each year thereafter. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 230% and a call option value of $0.1986, was $496,417. The options are being expensed over the vesting period. On April 7, 2016, the Company granted options to purchase a total of 130,000 fully vested shares of common stock as compensation for services to five employees. The options are exercisable over a ten year period at an exercise price of $0.22 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 238% and a call option value of $0.2183, was $28,382. The fully vested options were expensed in full upon the grant date. On November 20, 2015, the Company granted options to purchase 500,000 fully vested shares of common stock as compensation for services to a consultant. The options are exercisable over a three year period at an exercise price of $0.181 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 234% and a call option value of $0.1734, was $86,708. The fully vested options were expensed in full upon the grant date. Common Stock Option Issuances for the Year Ended September 30, 2015 On June 19, 2015, the Company granted options to purchase 100,000 shares of common stock as compensation for services to our Chief Financial Officer. The options vest ratably in quarterly increments over one year beginning September 19, 2015. The options are exercisable until June 19, 2025 at an exercise price of $0.33 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 237% and a call option value of $0.3274, was $32,744. The options were expensed over the vesting period. On June 1, 2015, the Company granted options to purchase 200,000 shares of common stock as compensation for services to our Chief Scientist. The options vest ratably in quarterly increments over two years beginning September 1, 2015. The options are exercisable until June 1, 2025 at an exercise price of $0.40 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 247% and a call option value of $0.3978, was $79,552. The options are being expensed over the vesting period. During the quarter ended December 31, 2014, the Company cancelled 1,219,589 non-plan options and issued 1,110,000 plan options and 500,000 warrants with exercise prices ranging from $0.40 to $0.85 per share, vesting immediately. The Company recorded the replacement of the stock options award as a modification of the terms of the cancelled awards, with the total compensation cost measured at the date of cancellation and replacement as being the sum of the portion of the grant-date fair value of the original award for which the requisite compensation expense had already been recognized at that date plus the incremental cost resulting from the cancellation and replacement. Common Stock Options Exercised for the Year Ended September 30, 2016 No stock options were exercised during the year ended September 30, 2016. Common Stock Options Exercised for the Year Ended September 30, 2015 On October 20, 2014, the Company issued 2,881 shares associated with the exercise of options with an exercise price of $3.30 per share and received $9,506 in cash. Common Stock Options Cancelled or Expired for the Year Ended September 30, 2016 On September 30, 2016, a total of 2,351 common stock options exercisable over a three year period from the original grant date of September 30, 2013 with an exercise price of $3.30 per share expired. No options expired during the year ended September 30, 2015. Common Stock Options Cancelled for the Year Ended September 30, 2015 On December 31, 2014, the Company cancelled 300,000 unvested common stock options exercisable over a three year period from the original grant date of April 15, 2014 with an exercise price of $0.20 per share. On December 31, 2014, the Company cancelled 100,000 unvested common stock options exercisable over a three year period from the original grant date of June 1, 2014 with an exercise price of $0.50 per share. The following is a summary of information about the stock options outstanding at September 30, 2016. Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.181 – $3.30 9,291,530 8.27 years $ 0.23 5,566,530 $ 0.25 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, 2016 September 30, 2015 Average risk-free interest rates 1.18 % 1.62 % Average expected life (in years) 9.58 4.49 Volatility 235 % 254 % The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the years ended September 30, 2016 and September 30, 2015, there were no options granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the years ended September 30, 2016 and 2015 was approximately $0.20 and $0.42 per option, respectively. The following is a summary of activity of outstanding common stock options: Weighted Average Number Exercise of Shares Price Balance, September 30, 2014 406,762 $ 0.30 Options expired (400,000 ) (0.30 ) Options cancelled - - Options granted 1,410,000 0.43 Options exercised (2,881 ) (3.30 ) Balance, September 30, 2015 1,413,881 0.43 Options expired (2,351 ) (0.30 ) Options cancelled - - Options granted 7,880,000 3.30 Options exercised - - Balance, September 30, 2016 9,291,530 $ 0.23 Exercisable, September 30, 2016 5,566,530 $ 0.25 Amortization of Stock Options A total of $994,178 and $663,626 of stock-based compensation expense was recognized from the amortization of options over their vesting period during the years ended September 30, 2016 and 2015, respectively. As of September 30, 2016, these options in the aggregate had no intrinsic value as the per share market price of $0.20 of the Company’s common stock as of such date was less than the weighted-average exercise price of these options of $0.23. Non-Plan Options During the three month period ended December 31, 2014, the Company issued options outside of the 2012 Plan to purchase 100,000 shares of common stock with an exercise price of $0.85, vesting quarterly over a period of one year, resulting in compensation expense of $82,826. These options were cancelled and re-issued as options under our 2012 plan in the quarter ended December 31, 2015. In addition to options granted under the 2012 Plan, at December 31, 2014, the Company had outstanding options to purchase 200,000 shares of common stock. During the three month period ended December 31, 2014, holders of non-plan options to purchase 200,000 shares of common stock surrendered such options to the Company for cancellation.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Common Stock Warrants	Note 14 – Common Stock Warrants In addition to warrants issued in connection with private placements of our securities as set forth in Note 12 above, we issued the following warrants to purchase our common stock as compensation for services. Common Stock Warrant Issuances for the Year Ended September 30, 2016 On June 6, 2016, the Company granted 659,800 fully vested common stock warrants as compensation for services to a consulting firm. The options are exercisable over a five year period at an exercise price of $0.1901 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 231% and a call option value of $0.1883, was $124,233 and was expensed in full on June 6, 2016. Common Stock Warrant Issuances for the Year Ended September 30, 2015 On December 31, 2014, the Company issued fully vested warrants to purchase 200,000 shares of common stock at an exercise price of $0.30 per share over three years to a service provider following the return for cancellation of prior stock grants and options totaling 200,000 shares. On December 30, 2014, the Company issued fully vested warrants to purchase 300,000 shares of common stock at an exercise price of $0.40 per share over three years to a former employee following the return for cancellation of prior stock grants and options totaling 300,000 shares. The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2016 (including those issued to both investors and service providers). Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price 0.1901 – $0.40 4,193,136 2.65 years $ 0.29 4,193,136 $ 0.29 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, 2016 September 30, 2015 Average risk-free interest rates 1.25 % 1.64 % Average expected life (in years) 3.50 3.00 Volatility 231 % 257 % The weighted average fair value of warrants granted with exercise prices at the current fair value of the underlying stock during the year ended September 30, 2016 was approximately $0.28 per warrant. The following is a summary of activity of outstanding common stock warrants: Weighted Average Number Exercise of Shares Price Balance, September 30, 2014 - $ - Warrants expired - - Warrants cancelled - - Warrants granted 500,000 0.36 Warrants exercised - - Balance, September 30, 2015 500,000 0.36 Warrants expired - - Warrants cancelled - - Warrants granted 3,693,136 0.28 Warrants exercised - - Balance, September 30, 2016 4,193,136 $ 0.29 Exercisable, September 30, 2016 4,193,136 $ 0.29 Amortization of Stock Warrants A total of $124,233 and $-0- of stock-based compensation expense was recognized from the amortization of warrants over their vesting period during the years ended September 30, 2016 and 2015, respectively. Subsidiary Warrants On April 19, 2014, Digipath Corp., a subsidiary of Digipath, Inc. which is dedicated to digital microscopy, granted five-year common stock Purchase Warrants to Steven Barbee and Eric Stoppenhagen (the “Consultants”) to purchase an aggregate of 6,000,000 shares of common stock of Digipath Corp. at an exercise price of $0.10 per share over a five (5) year period from the date of grant. The Company recorded a total of $343,533 of expense associated with the issuance of these warrants and recorded a non-controlling interest as a reduction to total stockholder’s equity on the Company’s balance sheet because the warrants were issued by the Company’s subsidiary. No continued allocation of the non-controlling interest in the equity of the subsidiary has been recognized, as the warrants hadn’t been exercised and Digipath, Inc. was still in control of 100% of the interests of the subsidiary as of September 30, 2015. The Company had recorded a total of total of $343,533 expense associated with warrants and recorded as a non-controlling interest because the warrants are issued by the subsidiary. The warrants were exercised on October 1, 2015 pursuant to the Company’s divestiture of Digipath Corp., as described in Note 3.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Lease Commitment The Company leases space for its lab operations in Las Vegas, Nevada. Amounts of minimum future annual commitments on a calendar year basis, including common area maintenance fees, under non-cancelable operating leases are as follows: 2016 $ 45,026 2017 184,483 2018 190,595 2019 196,951 2020 203,561 Total $ 820,616 In addition to this commitment, the Company pays monthly rent, on a month-to-month basis for leased industrial space located in Colorado at the rate of $2,738 per month. Rent expense was $211,525 and $206,570 for the years ended September 30, 2016 and 2015, respectively.

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax	Note 16 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended September 30, 2016 and 2015, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2016, the Company had approximately $6,811,300 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The effective income tax rate for the years ended September 30, 2016 and 2015 consisted of the following: September 30, 2016 2015 Federal statutory income tax rate 35.00 % 35.00 % State income taxes -% 3.95 % Change in valuation allowance (35.00 )% (38.95 )% Net effective income tax rate - - The components of the Company’s deferred tax asset are as follows: September 30, 2016 2015 Deferred tax assets: Net operating loss carry forwards $ 2,383,955 $ 2,328,375 Net deferred tax assets before valuation allowance $ 2,383,955 $ 2,328,375 Less: Valuation allowance (2,383,955 ) (2,328,375 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2016 and 2015, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events Preferred Stock Conversions On November 28, 2016, a shareholder converted 200,000 shares of Series A Preferred into 1,000,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On November 4, 2016, a shareholder converted 200,000 shares of Series A Preferred into 1,000,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 4, 2016, a shareholder converted 100,000 shares of Series A Preferred into 500,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized.

Nature of Business and Signif24

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our business units as of September 30, 2016 are described below. ● Digipath Labs, Inc ● The National Marijuana News Corp
Stock Split	Stock Split All share and per share amounts herein have been given retroactive effect to the 1-for-10 reverse stock split of the Company’s common stock effected May 27, 2015 (See Note 12).
Basis of Accounting	Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2016: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) (2) (3) The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Equity Method	Equity Method Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Consolidated Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Consolidated Statements of Operations. The Company’s carrying value in an equity method Investee company is reflected in the caption “Investment in Digipath Corp.” in the Company’s Consolidated Balance Sheets. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of three months or less. The Company had no cash equivalents as of September 30, 2016 and 2015.
Cash in Excess of FDIC Insured Limits	Cash in Excess of FDIC Insured Limits The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 under current regulations. The Company had approximately $-0- and $231,095 in excess of FDIC insured limits at September 30, 2016 and 2015, respectively. The Company has not experienced any losses in such accounts.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $-0- and $36,715 as of September 30, 2016 and 2015, respectively.
Inventory	Inventory Inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out method. Inventory consists of digital slide scanners and slide scanner parts.
Fixed Assets	Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 2-3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements 6 years Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which have extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. The Company recognized impairment losses on the disposal of fixed assets of $-0- and $8,303 during the years ended September 30, 2016 and 2015, respectively. Our intellectual property is comprised of indefinite-lived brand name acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. The Company recognized an impairment loss on the carrying value of its investment in TissueBLOX TM
Marketable Securities	Marketable Securities The Company classifies its debt and marketable equity securities into held-to-maturity, trading, or available-for-sale categories. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders’ equity.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. With respect to our cannabis lab testing revenues, we sell our services on a determinable fixed fee per test, or panel of tests basis, and offer a discounted price for customers that agree to enter into exclusive, long term contracts. We typically require payment within thirty days of the delivery of results. Revenues are recognized upon the substantial completion of the tests when collectability is reasonably assured, which is usually upon delivery of results to the customer.
Advertising Costs	Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $121,610 and $139,119 for the years ended September 30, 2016 and 2015, respectively.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2016 and 2015, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August, 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In June, 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718) . In March, 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March, 2016, the FASB issued ASU No. 2016-07, Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. In March, 2016, the FASB issued ASU No. 2016-04, Liabilities—Extinguishments of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Products In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Nature of Business and Signif25

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2016: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) (2) (3)
Schedule of Estimated Useful Lives of Fixed Assets Property, Plant and Equipment	The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 2-3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements 6 years

Discontinued Business Compone26

Discontinued Business Component (Tables)	12 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Schedule of Discontinued Business Component	The operating results of the Digital Pathology business for the year ended September 30, 2015 (prior to our divestment of control of this business), which have been extracted and presented as “Loss from operations of discontinued business component” within the statements of operations, are summarized below: For the Year Ended September 30, 2015 Revenues $ 395,718 Cost of sales 360,652 Gross profit 35,066 Expenses: General and administrative 433,569 Research and development 220,432 Total operating expenses 654,001 Net operating loss, net of tax (618,935 ) Other income 363 Net loss, net of tax $ (618,572 )

Fair Value of Financial Instr27

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2016 and 2015, respectively: Fair Value Measurements at September 30, 2016 Level 1 Level 2 Level 3 Assets Cash $ 135,390 $ - $ - Available-for-sale securities 9,200 - - Total assets 144,590 - - Liabilities None - - - Total liabilities - - - $ 144,590 $ - $ - Fair Value Measurements at September 30, 2015 Level 1 Level 2 Level 3 Assets Cash $ 481,095 $ - $ - Intellectual properties 14,000 - - Total assets 495,095 - - Liabilities None - - - Total liabilities - - - $ 495,095 $ - $ -

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2016 and 2015: For the Years Ended September 30, 2016 2015 Software $ 121,617 $ 131,636 Office equipment 36,080 35,467 Furniture and fixtures 2,357 14,607 Lab equipment 811,623 835,006 Leasehold improvements 487,066 487,066 1,458,743 1,503,782 Less: accumulated depreciation (318,995 ) (130,091 ) Total $ 1,139,748 $ 1,373,691

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	12 Months Ended
	Sep. 30, 2016
Schedule of Investments [Abstract]
Schedule of Available-for-Sale Securities	Available-for-sale securities consist of the following at September 30, 2016: Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Income Income Value Common stock $ 50,000 - $ (40,800 ) $ 9,200 Total available-for-sale securities $ 50,000 - $ (40,800 ) $ 9,200

Deferred Revenues (Tables)

Deferred Revenues (Tables)	12 Months Ended
	Sep. 30, 2016
Deferred Revenue Disclosure [Abstract]
Schedule of Deferred Revenues	Deferred revenues consist of the following at September 30, 2016 and 2015, respectively. For the Years Ended September 30, 2016 2015 Unearned advertising revenue $ - $ 4,167 Unearned software support - 68,954 Total $ - $ 73,121

Common Stock Options (Tables)

Common Stock Options (Tables)	12 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at September 30, 2016. Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.181 – $3.30 9,291,530 8.27 years $ 0.23 5,566,530 $ 0.25
Schedule of Option Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, 2016 September 30, 2015 Average risk-free interest rates 1.18 % 1.62 % Average expected life (in years) 9.58 4.49 Volatility 235 % 254 %
Summary of Common Stock Options Activity Outstanding	The following is a summary of activity of outstanding common stock options: Weighted Average Number Exercise of Shares Price Balance, September 30, 2014 406,762 $ 0.30 Options expired (400,000 ) (0.30 ) Options cancelled - - Options granted 1,410,000 0.43 Options exercised (2,881 ) (3.30 ) Balance, September 30, 2015 1,413,881 0.43 Options expired (2,351 ) (0.30 ) Options cancelled - - Options granted 7,880,000 3.30 Options exercised - - Balance, September 30, 2016 9,291,530 $ 0.23 Exercisable, September 30, 2016 5,566,530 $ 0.25

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2016 (including those issued to both investors and service providers). Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price 0.1901 – $0.40 4,193,136 2.65 years $ 0.29 4,193,136 $ 0.29
Schedule of Warrant Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan	The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, 2016 September 30, 2015 Average risk-free interest rates 1.25 % 1.64 % Average expected life (in years) 3.50 3.00 Volatility 231 % 257 %
Summary of Common Stock Warrants Activity Outstanding	The following is a summary of activity of outstanding common stock warrants: Weighted Average Number Exercise of Shares Price Balance, September 30, 2014 - $ - Warrants expired - - Warrants cancelled - - Warrants granted 500,000 0.36 Warrants exercised - - Balance, September 30, 2015 500,000 0.36 Warrants expired - - Warrants cancelled - - Warrants granted 3,693,136 0.28 Warrants exercised - - Balance, September 30, 2016 4,193,136 $ 0.29 Exercisable, September 30, 2016 4,193,136 $ 0.29

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payment Under Operating Leases	The Company leases space for its lab operations in Las Vegas, Nevada. Amounts of minimum future annual commitments on a calendar year basis, including common area maintenance fees, under non-cancelable operating leases are as follows: 2016 $ 45,026 2017 184,483 2018 190,595 2019 196,951 2020 203,561 Total $ 820,616

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The effective income tax rate for the years ended September 30, 2016 and 2015 consisted of the following: September 30, 2016 2015 Federal statutory income tax rate 35.00 % 35.00 % State income taxes -% 3.95 % Change in valuation allowance (35.00 )% (38.95 )% Net effective income tax rate - -
Schedule of Deferred Tax Asset	The components of the Company’s deferred tax asset are as follows: September 30, 2016 2015 Deferred tax assets: Net operating loss carry forwards $ 2,383,955 $ 2,328,375 Net deferred tax assets before valuation allowance $ 2,383,955 $ 2,328,375 Less: Valuation allowance (2,383,955 ) (2,328,375 ) Net deferred tax assets $ - $ -

Nature of Business and Signif35

Nature of Business and Significant Accounting Policies (Details Narrative)	Sep. 15, 2016USD ($)	May 27, 2015	Sep. 30, 2016USD ($)Segments	Sep. 30, 2015USD ($)
Reverse stock split description		1-for-10 reverse stock split
Percentage of equity method interest			100.00%
Number of reportable segment | Segments			2
Cash equivalents
Cash maximum insured limits by FDIC			250,000
Exceeded insurance amount by FDIC			0	231,095
Allowance for doubtful accounts receivable			0	36,715
Impairment losses on the disposal of fixed assets			0	8,303
Impairment loss on the carrying value of investment				300,000
Repayment of investment impaired				300,000
Lease obligations payable	$ 350,000
Unpaid sublease payments	50,000
Operating lease payments receivable	100,000
Monthly rental payments	$ 50,000
Advertising and promotions expense			$ 121,610	$ 139,119
Minimum [Member]
Percentage of equity method interest			20.00%
Maximum [Member]
Percentage of equity method interest			50.00%

Nature of Business and Signif36

Nature of Business and Significant Accounting Policies - Schedule of Entities Under Common Control and Ownership (Details) - Entities Under Common Control and Ownership [Member]	12 Months Ended
	Sep. 30, 2016
Name of Entity	Digipath, Inc.	[1],[2]
State of Incorporation	Nevada
Relationship	Parent
Name of Entity	Digipath Labs, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	TNM News, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	GroSciences, Inc.	[1],[3]
State of Incorporation	Colorado
Relationship	Subsidiary
[1]	All entities are in the form of a corporation.
[2]	Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above were wholly-owned by Digipath, Inc., the parent company.
[3]	Entity formed for prospective purposes, but has not incurred any income or expenses to date.

Nature of Business and Signif37

Nature of Business and Significant Accounting Policies - Schedule of Estimated Useful Lives of Fixed Assets Property, Plant and Equipment (Details)	12 Months Ended
	Sep. 30, 2016
Software [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	2 years
Software [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Furniture And Fixtures [Member]
Property, Plant and Equipment, Useful Life	5 years
Lab Equipment [Member]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	6 years

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (10,431,531)	$ (7,847,418)

Discontinued Business Compone39

Discontinued Business Component (Details Narrative)	Sep. 30, 2016	Oct. 31, 2015
Own minority interest	100.00%
DigiPath Corp [Member]
Own minority interest		33.30%

Discontinued Business Compone40

Discontinued Business Component - Schedule of Discontinued Business Component (Details)	12 Months Ended
	Sep. 30, 2015USD ($)
Discontinued Business Component - Schedule Of Discontinued Business Component Details
Revenues	$ 395,718
Cost of sales	360,652
Gross profit	35,066
General and administrative	433,569
Research and development	220,432
Total operating expenses	654,001
Net operating loss, net of tax	(618,935)
Other income	363
Net loss, net of tax	$ (618,572)

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 21, 2016	Oct. 02, 2015	Jun. 19, 2015	Jun. 02, 2015	Sep. 30, 2016	Sep. 30, 2015
Number of warrants to purchase of common stock shares					7,880,000	1,410,000
Fair value of common stock on the date of grant					$ 295,158	$ 224,012
Fair value measurements, volatility rate			237.00%	247.00%	235.00%	254.00%
DigiPath Corp [Member]
Indebtedness owed		$ 18,201
Mr. Barbee [Member] | DigiPath Corp [Member]
Number of warrants to purchase of common stock shares		3,000,000
Mr. Barbee [Member] | DigiPath Corp [Member] | Minimum [Member]
Common stock exercise price		$ 0.0333333
Mr. Barbee [Member] | DigiPath Corp [Member] | Maximum [Member]
Common stock exercise price		$ 0.10
Mr. Denkin [Member]
Option to purchase shares of common stock for services	2,500,000
Fair value measurements, volatility rate	230.00%
Mr. Denkin [Member] | Amended and Restated Employment Agreement [Member]
Initial base salary per annum	$ 192,000
Car allowance per month	$ 750
Number of warrants to purchase of common stock shares	2,500,000
Common stock exercise price	$ 0.20
Chief Financial Officer [Member]
Number of warrants to purchase of common stock shares			100,000
Common stock exercise price			$ 0.33
Option to purchase shares of common stock for services			100,000		300,000
Fair value of common stock on the date of grant					$ 59,970
Options exercisable description			The options are exercisable until June 19, 2025
Fair value measurements, volatility rate			237.00%
Call option value			$ 0.3274
Stock option value			$ 32,744
Chief Financial Officer [Member] | DigiPath Corp [Member]
Option to purchase shares of common stock for services					3,000,000
Fair value of common stock on the date of grant					$ 59,970
Percentage of outstanding shares of common stock					33.34%
Third Party [Member] | DigiPath Corp [Member] | Series A Preferred Stock [Member]
Number of warrants to purchase of common stock shares					3,000,000
Number of preferred stock shares and surrender and cancellation during the period					60,000
Aggregate purchase price of common stock					$ 100,000
Common stock warrant termination description					terminate a previously held warrant to purchase 3,000,000 shares of common stock of DigiPath Corp.
Employment Agreement [Member] | Joseph J. Bianco [Member]
Agreement terms	3 years
Initial base salary per annum	$ 96,000
Car allowance per month	$ 1,250
Number of warrants to purchase of common stock shares	4,750,000
Employment Agreement [Member] | Joseph J. Bianco [Member] | Chief Executive Officer [Member]
Common stock exercise price	$ 0.20

Fair Value of Financial Instr42

Fair Value of Financial Instruments (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Impairment losses on intellectual properties	$ 0	$ 300,000

Fair Value of Financial Instr43

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Level 1 [Member]
Cash	$ 135,390	$ 481,095
Available-for-sale securities	9,200
Intellectual properties		14,000
Assets	144,590	495,095
Total liabilities
Total	144,590	495,095
Level 2 [Member]
Cash
Available-for-sale securities
Intellectual properties
Assets
Total liabilities
Total
Level 3 [Member]
Cash
Available-for-sale securities
Intellectual properties
Assets
Total liabilities
Total

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Receivables [Abstract]
Accounts receivable	$ 98,441	$ 6,146
Allowance for uncollectible accounts	$ 0	$ 36,715

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory		$ 192,561
Allowance for inventory obsolescence	0	0
Inventory written off	$ 0	$ 73,179

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Oct. 01, 2016
Fixed assets book value			$ 3,122
Gain or loss recognized on disposals
Loss on disposal of leasehold improvements		8,303
Capitalized improvements with historical cost basis		13,586
Depreciation and amortization expense	$ 244,580	$ 77,813
Furniture and Fixtures [Member]
Fixed assets historical cost basis			48,779
Fixed assets accumulated depreciation and amortization			48,779
Software [Member]
Fixed assets historical cost basis			10,019
Fixed assets accumulated depreciation and amortization			$ 6,897

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Software	$ 121,617	$ 131,636
Office equipment	36,080	35,467
Furniture and fixtures	2,357	14,607
Lab equipment	811,623	835,006
Leasehold improvements	487,066	487,066
Fixed Assets, Gross	1,458,743	1,503,782
Less: accumulated depreciation	(318,995)	(130,091)
Total	$ 1,139,748	$ 1,373,691

Available-for-Sale Securities48

Available-for-Sale Securities (Details Narrative) - Blue Line Protection Group, Inc [Member]	1 Months Ended
	Mar. 31, 2015USD ($)shares
Number of common stock shares acquire during the period | shares	400,000
Number of common stock share value acquired during the period | $	$ 50,000

Available-for-Sale Securities -

Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Common stock	$ 9,200
Total available-for-sale securities	9,200	$ 14,000
Amortized Cost [Member]
Common stock	50,000
Total available-for-sale securities	50,000
Gains In Accumulated Other Comprehensive Income [Member]
Common stock
Total available-for-sale securities
Losses In Accumulated Other Comprehensive Income [Member]
Common stock	(40,800)
Total available-for-sale securities	$ (40,800)

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	Sep. 15, 2016	Sep. 30, 2016	Sep. 30, 2015
Intangible Assets Details Narrative
Losses on impairment			$ 300,000
Loss on impairment of intangible asset			300,000
Repay investment impaired			$ 300,000
Lease obligations payable	$ 350,000
Unpaid sublease payment	50,000
Operating lease payments receivable	100,000
Monthly rental payments	$ 50,000

Deferred Revenues - Schedule of

Deferred Revenues - Schedule of Deferred Revenues (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Deferred Revenue		$ 73,121
Unearned Advertising Revenue [Member]
Deferred Revenue		4,167
Unearned Software Support [Member]
Deferred Revenue		$ 68,954

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Jul. 02, 2016	May 02, 2016	Apr. 29, 2016	Apr. 14, 2016	Apr. 12, 2016	Apr. 07, 2016	Mar. 15, 2016	Feb. 17, 2016	Feb. 02, 2016	Jan. 19, 2016	Jan. 02, 2016	Dec. 21, 2015	Nov. 23, 2015	Aug. 10, 2015	Jun. 19, 2015	Jun. 02, 2015	May 27, 2015	Oct. 20, 2014	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015
Reverse stock split																	1-for-10 reverse stock split
Common stock, shares authorized																					90,000,000	90,000,000
Number of reverse stock split authorized shares decreased ratably shares of common stock																	90,000,000
Preferred stock, shares authorized																					10,000,000	10,000,000
Preferred stock, par value																					$ 0.001	$ 0.001
Preferred stock, shares issued																					3,520,442	4,351,442
Preferred stock, shares outstanding																					3,520,442	4,351,442
Percentage of equity beneficial ownership																					100.00%
Common stock par value																					$ 0.001	$ 0.001
Common stock authorized																					90,000,000	90,000,000
Common stock, shares issued																					22,491,041	13,762,705
Common Stock, shares outstanding																					22,491,041	13,762,705
Number of common stock purchased through issuance of warrants		100,000	166,667	166,667	83,334	166,667	1,666,667	83,333		333,334		166,667	100,000
Warrants exercise price per share		$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30		$ 0.30		$ 0.30	$ 0.40								$ 0.28
Warrants period		36 months	36 months	36 months	36 months	36 months	36 months	36 months		36 months		36 months	36 months
Proceeds from warrants exercisable		$ 15,000	$ 25,000	$ 25,000	$ 12,500	$ 25,000	$ 250,000	$ 12,500		$ 50,000		$ 25,000	$ 20,000
Common stock issued for services																					$ 295,158	$ 224,012
Stock-based compensation expense																				$ 845,540
Issuance of common stock shares																			40,000
Number of common stock cancelled shares																			75,000
Shares issued common stock for compensation expense																			12,500
Share issued in exercise stock option																		2,881				(2,881)
Stock option exercise price per share															$ 0.33	$ 0.40		$ 3.30				$ 3.30
Proceeds from stock option exercised																		$ 9,506				$ 9,506
Minimum [Member]
Percentage of equity beneficial ownership																					20.00%
Maximum [Member]
Percentage of equity beneficial ownership																					50.00%
Non-Plan Options [Member]
Stock-based compensation expense																				$ 82,826
Number of common stock cancelled shares																				200,000
Debt instrument cancelled during the period																				1,219,589
Stock option exercise price per share																				$ 0.85
Plan Options [Member]
Debt instrument cancelled during the period																				1,110,000
Stock option exercise price per share																					$ 0.20	$ 0.42
Vesting [Member]
Stock-based compensation expense																			$ 23,063
Issuance of Vesting Portion [Member]
Stock-based compensation expense																				$ 114,083
Vesting Prior Periods Awards [Member]
Stock-based compensation expense																				$ 68,333
Consultants [Member]
Stock issued for services	580,000								300,000		500,000										120,000
Common stock issued for services	$ 104,980								$ 45,720		$ 70,000										$ 23,988
Stock-based compensation expense									$ 30,480		$ 52,500
Investor [Member]
Stock issued for services											40,000
Common stock issued for services											$ 8,000
CFO [Member]
Stock issued for services															100,000						300,000
Common stock issued for services																					$ 59,970
Series A Convertible Preferred Stock [Member]
Preferred stock, shares designated																					6,000,000
Series A Preferred Stock [Member]
Preferred stock, shares issued																					3,520,442
Preferred stock, shares outstanding																					3,520,442
Preferred stock convertible into common stock at fixed conversion price per share																					$ 0.20
Preferred stock convertible into common stock shares																					17,602,210
Percentage of equity beneficial ownership																					4.99%
Stock conversion, shares converted																					771,000	1,498,558
Stock conversion, shares issued																					3,855,000	7,721,685
Restricted Common Stock [Member]
Stock issued for services														25,000
Common stock issued for services														$ 5,887
Warrant [Member]
Debt instrument cancelled during the period																				500,000
Warrant [Member] | Minimum [Member]
Warrants exercise price per share																				$ 0.30
Warrant [Member] | Maximum [Member]
Warrants exercise price per share																				$ 0.85
Common Stock [Member]
Stock issued for services																					1,840,000	237,545
Common stock issued for services																					$ 1,840	$ 237
Issuance of common stock shares																				160,000
Share issued in exercise stock option																				2,881		2,881
Stock option exercise price per share																				$ 3.30
Proceeds from stock option exercised																				$ 9,506

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)	Jun. 21, 2016	Apr. 07, 2016	Nov. 20, 2015	Jun. 19, 2015	Jun. 02, 2015	Dec. 31, 2014	Oct. 20, 2014	Jun. 21, 2012	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	May 02, 2016	Apr. 29, 2016	Apr. 14, 2016	Apr. 12, 2016	Mar. 15, 2016	Feb. 17, 2016	Jan. 19, 2016	Dec. 21, 2015	Nov. 23, 2015
Stock option exercise price per share				$ 0.33	$ 0.40		$ 3.30					$ 3.30
Volatility rate				237.00%	247.00%						235.00%	254.00%
Number of shares granted fully vested common stock option											7,880,000	1,410,000
Maximum date to exercise the option				Jun. 19, 2025	Jun. 1, 2025
Stock compensation expense										$ 845,540
Warrants exercise price per share		$ 0.30									$ 0.28		$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.40
Share issued in exercise stock option							2,881					(2,881)
Proceeds from stock option exercised							$ 9,506					$ 9,506
Unvested common stock option shares cancelled									75,000
April 15, 2014 [Member]
Stock options exercisable period						3 years
Stock option exercise price per share						$ 0.20
Unvested common stock option shares cancelled						300,000
June 1, 2014 [Member]
Stock options exercisable period						3 years
Stock option exercise price per share						$ 0.50
Unvested common stock option shares cancelled						100,000
Warrant [Member]
Debt instrument cancelled during the period										500,000
Warrant [Member] | Minimum [Member]
Warrants exercise price per share						$ 0.30				$ 0.30
Warrant [Member] | Maximum [Member]
Warrants exercise price per share						$ 0.85				$ 0.85
Common Stock Options [Member] | September 30, 2013 [Member]
Stock options exercisable period											3 years
Stock option exercise price per share											$ 3.30
Share issued in exercise stock option											2,351
Non-Plan Options [Member]
Number of shares issued under stock plan										100,000
Stock option exercise price per share										$ 0.85
Number of shares granted fully vested common stock option										200,000
Stock compensation expense										$ 82,826
Debt instrument cancelled during the period										1,219,589
Unvested common stock option shares cancelled										200,000
Plan Options [Member]
Stock option exercise price per share											$ 0.20	$ 0.42
Debt instrument cancelled during the period										1,110,000
Amortization of common stock options											$ 994,178	$ 663,626
Options exercise price description											these options in the aggregate had no intrinsic value as the per share market price of $0.20 of the Company’s common stock as of such date was less than the weighted-average exercise price of these options of $0.23.
Call Option [Member]
Value of call option per share				$ 0.3274	$ 0.3978
Value of option				$ 32,744	$ 79,552
Mr.Bianco [Member]
Option to purchase shares of common stock for services	4,750,000
Stock options exercisable period	10 years
Stock option exercise price per share	$ 0.20
Common stock, vesting percentage	50.00%
Common stock, vesting thereafter	25.00%
Volatility rate	230.00%
Value of call option per share	$ 0.1986
Value of option	$ 943,193
Mr. Denkin [Member]
Option to purchase shares of common stock for services	2,500,000
Stock options exercisable period	10 years
Stock option exercise price per share	$ 0.20
Common stock, vesting percentage	50.00%
Common stock, vesting thereafter	25.00%
Volatility rate	230.00%
Value of call option per share	$ 0.1986
Value of option	$ 496,417
Five Employees [Member]
Stock option exercise price per share		$ 0.22
Volatility rate		238.00%
Value of call option per share		$ 0.2183
Value of option		$ 28,382
Number of shares granted fully vested common stock option		130,000
Consultant [Member]
Stock options exercisable period			3 years
Stock option exercise price per share			$ 0.181
Volatility rate			234.00%
Value of call option per share			$ 0.1734
Value of option			$ 86,708
Number of shares granted fully vested common stock option			500,000
CFO [Member]
Option to purchase shares of common stock for services				100,000							300,000
Volatility rate				237.00%
Number of shares granted fully vested common stock option				100,000
Chief Scientist [Member]
Number of shares granted fully vested common stock option					200,000
2012 Stock Incentive Plan [Member]
Number of shares issued under stock plan								11,500,000
2012 Plan [Member]
Number of shares granted fully vested common stock option										200,000

Common Stock Options - Summary

Common Stock Options - Summary of Common Stock Options Outstanding (Details)	12 Months Ended
	Sep. 30, 2016$ / sharesshares
Equity [Abstract]
Range of Exercise Price, Minimum	$ 0.181
Range of Exercise Price, Maximum	$ 3.30
Number of Options Outstanding | shares	9,291,530
Weighted Average Remaining Contractual Life	8 years 3 months 7 days
Weighted Average Exercise Price	$ 0.23
Number of Shares Exercisable | shares	5,566,530
Weighted Average Exercise Price Exercisable	$ 0.25

Common Stock Options - Schedule

Common Stock Options - Schedule of Option Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan (Details)	Jun. 19, 2015	Jun. 02, 2015	Sep. 30, 2016	Sep. 30, 2015
Equity [Abstract]
Average risk-free interest rates			1.18%	1.62%
Expected average term			9 years 6 months 29 days	4 years 5 months 27 days
Volatility	237.00%	247.00%	235.00%	254.00%

Common Stock Options - Summar56

Common Stock Options - Summary of Common Stock Options Activity Outstanding (Details) - $ / shares	Jun. 19, 2015	Jun. 02, 2015	Oct. 20, 2014	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Equity [Abstract]
Number of Shares Outstanding, Beginning balance					1,413,881	406,762
Number of Shares Options expired					(2,351)	(400,000)
Number of Shares Options cancelled				75,000
Number of Shares Options granted					7,880,000	1,410,000
Number of Shares Options exercised			2,881			(2,881)
Number of Shares Outstanding, Ending balance					9,291,530	1,413,881
Number of Shares Exercisable					5,566,530
Weighted Average Exercise Price, Outstanding, Beginning					$ 0.43	$ 0.30
Weighted Average Exercise Price, Options expired					(0.30)	(0.30)
Weighted Average Exercise Price, Options cancelled
Weighted Average Exercise Price, Options granted					0.30	0.43
Weighted Average Exercise Price, Options exercised	$ (0.33)	$ (0.40)	$ (3.30)			(3.30)
Weighted Average Exercise Price, Outstanding, Ending					0.23	0.43
Weighted Average Exercise Price, Exercisable					$ 0.25

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - USD ($)	Jun. 06, 2016	May 02, 2016	Apr. 29, 2016	Apr. 14, 2016	Apr. 12, 2016	Apr. 07, 2016	Mar. 15, 2016	Feb. 17, 2016	Jan. 19, 2016	Dec. 21, 2015	Nov. 23, 2015	Jun. 19, 2015	Jun. 02, 2015	Dec. 31, 2014	Oct. 20, 2014	Apr. 19, 2014	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Common stock warrants issued for services																		$ 1,118,411	$ 663,626
Warrants period		36 months	36 months	36 months	36 months	36 months	36 months	36 months	36 months	36 months	36 months
Warrants exercise price per share		$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.30	$ 0.40							$ 0.28
Number of common stock purchased through issuance of warrants		100,000	166,667	166,667	83,334	166,667	1,666,667	83,333	333,334	166,667	100,000
Exercise price of common stock												$ 0.33	$ 0.40		$ 3.30				$ 3.30
Number of common stock cancelled shares																	75,000
Consultants [Member]
Warrants period																5 years
Number of common stock purchased through issuance of warrants																6,000,000
Exercise price of common stock																$ 0.10
Expenses associated with issuance of warrants																$ 343,533
Common Stock Warrant [Member]
Number of common stock purchased through issuance of warrants														200,000
Exercise price of common stock														$ 0.30
Number of common stock cancelled shares														200,000
Amortization of stock warrants																		$ 124,233	$ 0
Common Stock Warrant One [Member]
Number of common stock purchased through issuance of warrants														300,000
Exercise price of common stock														$ 0.40
Number of common stock cancelled shares														300,000
Consulting Firm [Member]
Common stock warrants issued for services	$ 659,800
Warrants period	5 years
Warrants exercise price per share	$ 0.1901
Warrant volatility rate	231.00%
Value of call option per share	$ 0.1883
Value of option	$ 124,233
Digipath, Inc [Member]
Expenses associated with issuance of warrants																		$ 343,533
Percentage of ownership in noncontrolling interest																			100.00%

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Equity [Abstract]
Range of Exercise Price, Minimum	$ 0.1901
Range of Exercise Price, Maximum	$ 0.40
Number of Warrants Outstanding	4,193,136	500,000
Weighted Average Remaining Contractual Life	2 years 7 months 24 days
Weighted Average Exercise Price	$ 0.29
Number of Shares Exercisable	4,193,136
Weighted Average Exercise Price Exercisable	$ 0.29

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Warrant Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan (Details)	Jun. 19, 2015	Jun. 02, 2015	Sep. 30, 2016	Sep. 30, 2015
Average risk-free interest rates			1.18%	1.62%
Average expected life (in years)			9 years 6 months 29 days	4 years 5 months 27 days
Volatility	237.00%	247.00%	235.00%	254.00%
Warrant [Member]
Average risk-free interest rates			1.25%	1.64%
Average expected life (in years)			3 years 6 months	3 years
Volatility			231.00%	257.00%

Common Stock Warrants - Summa60

Common Stock Warrants - Summary of Common Stock Warrants Activity Outstanding (Details) - $ / shares	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Equity [Abstract]
Shares Outstanding, Beginning balance	500,000
Shares, Expired
Shares, Cancelled
Shares, Granted	3,693,136	500,000
Shares, Exercised
Shares Outstanding, Ending balance	4,193,136	500,000
Shares Exercisable	4,193,136
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.36
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Granted	0.28	0.36
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Outstanding, Ending	0.29	0.36
Weighted Average Exercise Price, Exercisable	$ 0.29

Commitments and Contingencies61

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Monthly rent payable	$ 2,738
Rent expense	$ 211,525	$ 206,570

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payment Under Operating Leases (Details)	Sep. 30, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 45,026
2,017	184,483
2,018	190,595
2,019	196,951
2,020	203,561
Total	$ 820,616

Income Tax (Details Narrative)

Income Tax (Details Narrative)	12 Months Ended
	Sep. 30, 2016USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 6,811,300
Operating loss expiration year	2,031

Income Tax - Schedule of Effect

Income Tax - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	35.00%	35.00%
State income taxes	0.00%	3.95%
Change in valuation allowance	(35.00%)	(38.95%)
Net effective income tax rate	0.00%	0.00%

Income Tax - Schedule of Deferr

Income Tax - Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 2,383,955	$ 2,328,375
Net deferred tax assets before valuation allowance	2,383,955	2,328,375
Less: Valuation allowance	(2,383,955)	(2,328,375)
Net deferred tax assets

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Series A Preferred Stock [Member] - Subsequent Event [Member] - shares	Nov. 28, 2016	Nov. 04, 2016	Oct. 04, 2016
Stock conversion, shares converted	200,000	200,000	100,000
Stock conversion, shares issued	1,000,000	1,000,000	500,000